- Home
- TXG vs CDTX Comparison
TXG vs CDTX Comparison
Compare TXG & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXG
- CDTX
- Stock Information
- Founded
- TXG 2012
- CDTX 2012
- Country
- TXG United States
- CDTX United States
- Employees
- TXG N/A
- CDTX N/A
- Industry
- TXG Biotechnology: Laboratory Analytical Instruments
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TXG Industrials
- CDTX Health Care
- Exchange
- TXG Nasdaq
- CDTX Nasdaq
- Market Cap
- TXG 1.6B
- CDTX 1.6B
- IPO Year
- TXG 2019
- CDTX 2015
- Fundamental
- Price
- TXG $12.86
- CDTX $64.85
- Analyst Decision
- TXG Buy
- CDTX Strong Buy
- Analyst Count
- TXG 12
- CDTX 11
- Target Price
- TXG $13.54
- CDTX $57.00
- AVG Volume (30 Days)
- TXG 2.2M
- CDTX 493.2K
- Earning Date
- TXG 10-28-2025
- CDTX 11-06-2025
- Dividend Yield
- TXG N/A
- CDTX N/A
- EPS Growth
- TXG N/A
- CDTX N/A
- EPS
- TXG N/A
- CDTX N/A
- Revenue
- TXG $644,466,000.00
- CDTX N/A
- Revenue This Year
- TXG $2.15
- CDTX N/A
- Revenue Next Year
- TXG N/A
- CDTX N/A
- P/E Ratio
- TXG N/A
- CDTX N/A
- Revenue Growth
- TXG 2.02
- CDTX N/A
- 52 Week Low
- TXG $6.78
- CDTX $10.14
- 52 Week High
- TXG $24.38
- CDTX $69.36
- Technical
- Relative Strength Index (RSI)
- TXG 45.60
- CDTX 54.45
- Support Level
- TXG $12.39
- CDTX $61.10
- Resistance Level
- TXG $13.39
- CDTX $69.21
- Average True Range (ATR)
- TXG 0.61
- CDTX 3.28
- MACD
- TXG -0.12
- CDTX -0.25
- Stochastic Oscillator
- TXG 21.74
- CDTX 47.09
About TXG 10x Genomics Inc.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.